Global Finance News
22 Jun 2026, 14:13
AbbVie Rallies After $10.9 Billion Apogee Acquisition and New Wells Fargo Price Target
AbbVie (NYSE: ABBV) rose 4.6% after announcing a $10.9 billion acquisition of Apogee Therapeutics and receiving a new $260 price target from Wells Fargo, reinforcing investor confidence in the company's long-term growth strategy.
Under the agreement, AbbVie will acquire Apogee for $135.11 per share in cash, adding a promising pipeline of immunology and respiratory disease treatments to its portfolio. The deal is centered around zumilokibart (APG777), a late-stage treatment for atopic dermatitis, as well as additional programs targeting asthma and other inflammatory diseases.
Management believes the acquisition will strengthen AbbVie's leadership in immunology, one of its most important therapeutic areas, while creating a new growth platform beyond its existing blockbuster products. The company highlighted the potential for multiple future blockbuster therapies and expects the transaction to become accretive to earnings beginning in 2032.
The positive market reaction suggests investors view the acquisition as a strategic move to expand AbbVie's pipeline and support long-term revenue growth. Combined with Wells Fargo's newly established $260 price target, the announcement helped drive shares sharply higher as investors welcomed the company's continued investment in high-growth areas of biotechnology.
AbbVie (NYSE: ABBV) rose 4.6% after announcing a $10.9 billion acquisition of Apogee Therapeutics and receiving a new $260 price target from Wells Fargo, reinforcing investor confidence in the company's long-term growth strategy.
Under the agreement, AbbVie will acquire Apogee for $135.11 per share in cash, adding a promising pipeline of immunology and respiratory disease treatments to its portfolio. The deal is centered around zumilokibart (APG777), a late-stage treatment for atopic dermatitis, as well as additional programs targeting asthma and other inflammatory diseases.
Management believes the acquisition will strengthen AbbVie's leadership in immunology, one of its most important therapeutic areas, while creating a new growth platform beyond its existing blockbuster products. The company highlighted the potential for multiple future blockbuster therapies and expects the transaction to become accretive to earnings beginning in 2032.
The positive market reaction suggests investors view the acquisition as a strategic move to expand AbbVie's pipeline and support long-term revenue growth. Combined with Wells Fargo's newly established $260 price target, the announcement helped drive shares sharply higher as investors welcomed the company's continued investment in high-growth areas of biotechnology.